Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2012; 137(19): 1003-1006
DOI: 10.1055/s-0032-1304928
DOI: 10.1055/s-0032-1304928
Übersicht | Review article
Diabetologie, Onkologie
Diabetes und Krebsrisiko
Diabetes and cancer riskFurther Information
Publication History
19 February 2012
22 March 2012
Publication Date:
27 April 2012 (online)
-
Literatur
- 1 Barb D et al. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007; 86: 858-866
- 2 Blin P et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012; 55: 644-653
- 3 Bowker SL et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258
- 4 Chowdhury TA. Diabetes and cancer. QJM 2010; 103: 905-915
- 5 Coughlin SS et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160-1167
- 6 Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777
- 7 Currie CJ et al. Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. Diabetes Care 2012; 35: 299-304
- 8 Denley A et al. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol 2007; 27: 3569-3577
- 9 Dos Santos E et al. Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 2008; 20: 971-977
- 10 Drucker DJ et al. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 2011; 96: 2027-2031
- 11 Giovannucci E et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-1685
- 12 Goodwin PJ et al. Fasting insulin and outcome in early-stage breast cancer. J Clin Oncol 2002; 20: 42-51
- 13 Hassan MM et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116: 1938-1946
- 14 Heron M. Deaths: leading causes for 2007. Natl Vital Stat Rep 2011; 59: 1-95
- 15 Heuson JC, Legros N, Heimann R. Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Research 1972; 32: 233-238
- 16 Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthraceneinduced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Research 1972; 32: 226-232
- 17 Inoue M et al. Diabetes mellitus and the risk of cancer. Arch Intern Med 2006; 166: 1871-1877
- 18 Jee SH et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202
- 19 Jemal A et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
- 20 Joslin EP et al. Diabetes and cancer. N Engl J Med 1959; 260: 486-488
- 21 Liu X et al. The impact of type 2 diabetes mellitus on cancer-specific survival: A follow-up study in sweden. Cancer 2012; 118: 1353-1361
- 22 Monami M et al. Sulphonylureas and cancer. Acta Diabetol 2009; 46: 279-284
- 23 Müssig K et al. Diabetes, Insulin, Insulinanaloga und Karzinome. Dtsch Med Wochenschr 2010; 135: 924-929
- 24 Müssig K et al. Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism?. Diabet Med 2011; 28: 276-286
- 25 Papa V et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990; 86: 1503-1510
- 26 Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008; 114: 63-70
- 27 Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012; 18: 40-50
- 28 Rapp K et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 2006; 49: 945-952
- 29 Ruiter R et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012; 55: 51-62
- 30 Stattin P et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007; 30: 561-567
- 31 Stefan N, Stumvoll M. Adiponectin--its role in metabolism and beyond. Horm Metab Res 2002; 34: 469-474
- 32 Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. British Journal of Cancer 2007; 96: 507-509
- 33 Stocks T et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 2009; 6: e1000201
- 34 Swerdlow AJ et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 2005; 92: 2070-2075
- 35 Tamae D et al. Mutagenesis and repair induced by the DNA advanced glycation end product N2-1-(carboxyethyl)-2'-deoxyguanosine in human cells. Biochemistry 2011; 50: 2321-2329
- 36 The Endogenous Hormones and Breast Cancer Collaborative Group. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncology 2010; 11: 530-542
- 37 Ullrich A et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985; 313: 756-761
- 38 Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033
- 39 Vigneri P et al. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-1123
- 40 Weinstein D et al. Insulin analogues display IGF-I-like mitogenic and antiapoptotic activities in cultured cancer cells. Diabete Metab Res Rev 2009; 25: 41-49
- 41 Whiting DR et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321
- 42 Wideroff L et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-1365
- 43 Wilson EB, Maher HC. Cancer and tuberculosis with some comments on cancer and other diseases. Am J Cancer 1932; 16: 227-250
- 44 Wuenschell GE et al. Mutagenic potential of DNA glycation: miscoding by (R)- and (S)-N2-(1-carboxyethyl)-2'-deoxyguanosine. Biochemistry 2010; 49: 1814-1821
- 45 Zavoral M et al. Molecular biology of pancreatic cancer. World J Gastroenterol 2011; 17: 2897-908
- 46 Zendehdel K et al. Cancer incidence in patients with type 1 diabetes mellitus. J Natl Cancer Inst 2003; 95: 1797-1800
- 47 Zhou XH et al. for the DECODE Study Group. Diabetes, prediabetes and cancer mortality. Diabetologia 2010; 53: 1867-1876